Table 1.
Characteristics of patients with advanced SCLC.
| Characteristics | No. of patients (n = 100) | Percentage (%) |
|---|---|---|
| Age (year), median (range) | 60 (32−82) | |
| <60 | 48 | 48 |
| ≥60 | 52 | 52 |
| Sex | ||
| Male | 88 | 88 |
| Female | 12 | 12 |
| Stage | ||
| LD | 26 | 26 |
| ED | 74 | 74 |
| Smoking history | ||
| Never smoke | 21 | 21 |
| Smoke | 79 | 79 |
| ICI Drugs | ||
| PD-1 inhibitor | 65 | 65 |
| PD-L1 inhibitor | 35 | 35 |
| Chemotherapy | ||
| Platinum plus etoposide | 87 | 87 |
| Nab-paclitaxel plus etoposide | 13 | 13 |
| ECOG PS | ||
| 0−1 | 94 | 94 |
| ≥2 | 6 | 6 |
| Brain metastasis | ||
| Yes | 22 | 22 |
| No | 78 | 78 |
| Liver metastasis | ||
| Yes | 24 | 24 |
| No | 76 | 76 |
| Bone metastasis | ||
| Yes | 29 | 29 |
| No | 71 | 71 |
| Treatment efficacy | ||
| PR | 60 | 60 |
| SD | 31 | 31 |
| PD | 9 | 9 |
| dNLR | ||
| <4.0 | 78 | 78 |
| ≥4.0 | 22 | 22 |
| LDH (U/L) | ||
| <283 | 75 | 75 |
| ≥283 | 25 | 25 |
| Pretreatment LIPI | ||
| Good | 64 | 64 |
| Intermediate | 25 | 25 |
| Poor | 11 | 11 |
LD, limited disease; ED, extensive disease; ECOG PS, Eastern Cooperative Oncology Group Performance Status; ICI, immune checkpoint inhibitor; PD-1, programmed cell death-1; PD-L1, programmed cell death-ligand 1; dNLR, derived neutrophil-to-lymphocyte ratio; LDH, lactate dehydrogenase; LIPI, Lung immune prognostic index; PR, partial response; SD, steady disease; PD, progressive disease.